摘要
复方天仙胶囊是以祛邪为主的抗癌中药制剂,从1984年至1988年在全国十六个医疗单位进行了治疗食管癌和胃癌的临床试验研究,共观察了807例患者。单独服用复方天仙胶囊治疗失去手术、放、化疗机会或经过治疗复发的晚期患者,通过对349例ⅢⅣ期食管癌和胃癌患者的近期临床疗效观察,结果表明复方天仙胶囊可明显抑制肿瘤的发展,缓解率为1.2％,好转率2.0％,稳定率77.0％。患者服药后生存质量普遍提高,并可明显减轻食管癌出现的吞咽困难以及癌性疼痛等症状。应用复方天仙胶囊配合放射治疗食管癌364例。配合联合化疗治疗食管癌69例患者,结果表明复方天仙胶囊可明显提高放化疗的疗效。放疗完全缓解率提高21.3％(P<0.01)。联合化疗完全缓解率提高17.7％(P7<0.05)。对25例食管癌手术前服用复方天仙胶囊患者切除的肿瘤标本进行病理组织学和电镜超微结构的免疫病理学研究,看到癌巢内外淋巴细胞和巨噬细胞反应明显增强,癌细胞核和胞浆细胞明显变性坏死。该药对消化道有一定刺激作用,1/3患者可出现轻度的灼心、恶心感,如采用饭后或调以蜂蜜送服等方法,可使反应减轻或消失。但对造血系统、心、肝、肾等脏器、神经系统和毛发、皮肤则未见毒性反应,使用安全。复方天仙胶囊的抗癌应用广泛,既可以用于治疗晚期癌,也可作为放化疗的增效剂或手术前服用,是一个具有中医特色,祛邪而不伤正的抗癌新药。
Compound Tian-Xian Capsule is an anticancer preparation made from several Chinese herbal medicines. From 1984 to 1988, 807 patients with carcinoma of esopha- gus and stomach were treated with the Compound Tian-Xian Capsule in 16 hospitals of China. Among these patients, 349 late cases were treated solely with the Compound Tian-Xian Capsule. Short-term effect of these 349 cases revealed CR+PR 1.2%, MR 2.0% and SD 77.0% of patients. And the quality of life was improved in all the patients with relief of dysphagia and pain. In the other 433 patients 364 were treated with the Compound Tian-Xian Capsule in combination with radiotherapy and 69 with chemotherapy. It was demonstrated that the Capsule enhanced the efficacy of radio- therapy and chemotherapy. The CR rates in the groups of patient treated with either radiotherapy or chemotherapy in combination with Compound Tian-Xian Capsule increased 21.3% (P<0.01) and 17.7% (P<0.05) respectively as compared with either of them singly. Under electron microscopic observation in 25 resected tumor specimens after treat- ment lymphocytic and macrophageal infiltration in and out of cancer foci increase dmarkedly, degeneration and necrosis of the nucleus and cytoplasmic organelle of cancer cells were observed. This Capsule irritated alimentary tract. In one third of the patients slight nausea and heartburn occurred. However they could be alleviated by taking the Capsule after meal or along with honey. No hematopoietic, cardiac, liver, kidney, nervous system or skin deleterious effect were seen.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
1990年第1期22-28,51,共8页
Chinese Journal of Clinical Oncology
